June 20, 2024 11:48 AM EDTUpdated June 21, 11:30 AM

Takeda budgets $230M for plasma therapy facility expansion in California

Anna Brown

News Reporter

As a part of Takeda’s larger plan to boost production of its plasma-derived therapies, the company is allocating $230 million to expand its manufacturing site …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Takeda budgets $230M for plasma therapy facility expansion in California

Anna Brown

News Reporter

Sign up to read this article for free.

PureTech CEO leaves just one week after longtime chair steps down

AstraZeneca says amyloidosis drug fails Phase 3 trials, but claims potential in undisclosed subgroup

Prime Medicine CSO departs, reveals new funding; FDA lifts partial hold on Kezar drug

Debiopharm licenses Repare’s first-in-class cancer drug for $10M upfront

Prasad again overrode FDA vaccine reviewers, this time on Moderna’s Covid shot for young kids

Updated: J&J's Stelara faces continued biosimilar competition, with Q2 revenue falling 43%

Take­da bud­gets $230M for plas­ma ther­a­py fa­cil­i­ty ex­pan­sion in Cal­i­for­nia

Anna Brown

News Reporter

Sign up to read this article for free.

more like this

PureTech CEO leaves just one week af­ter long­time chair steps down

As­traZeneca says amy­loi­do­sis drug fails Phase 3 tri­als, but claims po­ten­tial in undis­closed sub­group

Prime Med­i­cine CSO de­parts, re­veals new fund­ing; FDA lifts par­tial hold on Kezar drug

De­bio­pharm li­cens­es Re­pare’s first-in-class can­cer drug for $10M up­front

Prasad again over­rode FDA vac­cine re­view­ers, this time on Mod­er­na’s Covid shot for young kids

Up­dat­ed: J&J's Ste­lara faces con­tin­ued biosim­i­lar com­pe­ti­tion, with Q2 rev­enue falling 43%

Takeda budgets $230M for plasma therapy facility expansion in California

PureTech CEO leaves just one week after longtime chair steps down

AstraZeneca says amyloidosis drug fails Phase 3 trials, but claims potential in undisclosed subgroup

Prime Medicine CSO departs, reveals new funding; FDA lifts partial hold on Kezar drug

Debiopharm licenses Repare’s first-in-class cancer drug for $10M upfront

Prasad again overrode FDA vaccine reviewers, this time on Moderna’s Covid shot for young kids

Updated: J&J's Stelara faces continued biosimilar competition, with Q2 revenue falling 43%